These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17602337)

  • 1. [Systemic review and meta-analysis of tolerability and safety between different titration regimes of ropinirol dose in the treatment of Parkinson's disease].
    Chacon J
    Neurologia; 2007 Dec; 22(10):882-94. PubMed ID: 17602337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
    Kulisevsky J; Pagonabarraga J
    Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ropinirole: a review of its use in the management of Parkinson's disease.
    Matheson AJ; Spencer CM
    Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; (1):CD001516. PubMed ID: 11279718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2000; (3):CD001516. PubMed ID: 10908503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ropinirole in the symptomatic treatment of Parkinson's disease.
    Brooks DJ; Torjanski N; Burn DJ
    J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; (1):CD001517. PubMed ID: 11279719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2000; 2001(3):CD001517. PubMed ID: 10908504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.
    Etminan M; Gill S; Samii A
    Drug Saf; 2003; 26(6):439-44. PubMed ID: 12688834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, fixed-dose, dose-response study of ropinirole prolonged release in advanced Parkinson's disease.
    Zesiewicz TA; Chriscoe S; Jimenez T; Upward J; Davy M; VanMeter S
    Neurodegener Dis Manag; 2017 Feb; 7(1):61-72. PubMed ID: 28120630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
    Etminan M; Samii A; Takkouche B; Rochon PA
    Drug Saf; 2001; 24(11):863-8. PubMed ID: 11665873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ropinirole prolonged release: in advanced Parkinson's disease.
    Weber J; Keating GM
    CNS Drugs; 2009; 23(1):81-90. PubMed ID: 19062777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
    Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE
    N Engl J Med; 2000 May; 342(20):1484-91. PubMed ID: 10816186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label extension study to evaluate the safety of ropinirole prolonged release in Chinese patients with advanced Parkinson's disease.
    Zhang Z; Wang J; Zhang X; Chen S; Wang Z; Zhang B; Liu C; Qu Q; Cheng Y; Zhu R; Li J; Hu J; Cai M
    Curr Med Res Opin; 2015 Apr; 31(4):723-30. PubMed ID: 25586298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease.
    Rascol O; Lees AJ; Senard JM; Pirtosek Z; Montastruc JL; Fuell D
    Clin Neuropharmacol; 1996 Jun; 19(3):234-45. PubMed ID: 8726542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease.
    Schrag AE; Brooks DJ; Brunt E; Fuell D; Korczyn A; Poewe W; Quinn NP; Rascol O; Stocchi F
    Clin Neuropharmacol; 1998; 21(3):169-75. PubMed ID: 9617508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study.
    Zhang Z; Wang J; Zhang X; Chen S; Wang Z; Zhang B; Liu C; Qu Q; Cheng Y; Li J; Cao H; Cai M; Zhu R
    Parkinsonism Relat Disord; 2013 Nov; 19(11):1022-6. PubMed ID: 23932066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.